Roby Thomas
Hematology & Oncology · Pittsburgh, PANPI 1912266735
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,985 of the $4,893 with a category attached, or 61.0%. 13 manufacturers reported payments, led by Dendreon Pharmaceuticals LLC at 39.5% of the total. Reporting peaked in 2019 at $1,897 and has fallen 94.2% since, to $110 in 2025.
Across 30 payments — averaging $163.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dendreon Pharmaceuticals LLC$2K
- Advanced Accelerator Applications$1K
- AstraZeneca$590
- Heron Therapeutics, Inc.$227
- Ipsen Biopharmaceuticals, Inc$213
- Beigene USA, Inc.$118
- plus $328 from 7 others
Across 21 payments — averaging $5802.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Products Limited$55K
- Ipsen Bioscience Inc.$33K
- E.r. Squibb & Sons, L.L.C.$18K
- AstraZeneca$16K
- Bristol Myers Squibb$131
What the payments were for
- Consulting fees$2,98561%
- Food & beverage$1,83938%
- Education$681%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dendreon Pharmaceuticals LLC | 4 | $1,932 |
| Advanced Accelerator Applications | 1 | $1,485 |
| AstraZeneca | 7 | $590 |
| Heron Therapeutics, Inc. | 2 | $227 |
| Ipsen Biopharmaceuticals, Inc | 2 | $213 |
| Beigene USA, Inc. | 1 | $118 |
| Gilead | 2 | $111 |
| Bristol Myers Squibb | 5 | $82 |
| Tempus AI, Inc | 2 | $36 |
| Telix Pharmaceuticals | 1 | $33 |
| Caris MPI, Inc. | 1 | $28 |
| Varian Medical Systems, Inc. | 1 | $20 |
| Cardinal Health 414 LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROVENGE$1,932
- SOMATULINE DEPOT$213
- ONIVYDE$213
- BRUKINSA$118
- SUSTOL$114
How this compares
$4,893 in reported general payments places this provider in the 65th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 15 | $204,687 |
| ErleadaApalutamide | 11 | $151,797 |
| OrgovyxRelugolix | 52 | $140,017 |
| Abiraterone Acetate | 54 | $105,591 |
| EliquisApixaban | 31 | $26,315 |
| Prochlorperazine Maleate | 13 | $490 |
| Prednisone | 125 | $484 |
| Ondansetron Hcl | 23 | $386 |
| Gabapentin | 24 | $157 |
| Potassium Chloride | 12 | $137 |
| Levothyroxine Sodium | 20 | $125 |
| Pantoprazole Sodium | 18 | $95 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Pittsburgh
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Alexander BarsoukPittsburgh$674K
- Hashem YounesPittsburgh$435K
- Taofeek OwonikokoPittsburgh$346K
- Jason LukePittsburgh$300K
- Ahmad TarhiniPittsburgh$216K
- Diwakar DavarPittsburgh$104K
- Jing Zhou HouPittsburgh$78K
- Vikram GorantlaPittsburgh$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.